Growth and Molecular Interactions of the Anti-Egfr Antibody Cetuximab and the DNA Cross-Linking Agent Cisplatin in Gefitinib-Resistant MDA-MB-468 Cells: New Prospects in the Treatment of Triple-Negative/Basal-Like Breast Cancer

International Journal of Oncology - Greece
doi 10.3892/ijo_00000106
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Spandidos Publications

Related search

The Regulation and Mechanisms of EGFR-mediated Apoptosis in MDA-MB-468 Cells.

English

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2013English

Triple-Negative (Basal-Like) Breast Cancer: A New Entity

Breast Cancer Research
Cancer ResearchOncology
2007English

Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast Cancer

2019English

Hypoxia-Induced Reactive Oxygen Species Mediate N-Cadherin and SERPINE1 Expression, EGFR Signalling and Motility in MDA-MB-468 Breast Cancer Cells

Scientific Reports
Multidisciplinary
2017English

Cetuximab PET Delineated Changes in Cellular Distribution of EGFR Upon Dasatinib Treatment in Triple Negative Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2020English

Are Triple Negative Tumours and Basal-Like Breast Cancer Synonymous?

Breast Cancer Research
Cancer ResearchOncology
2007English

Synthetic Lethal Interactions Between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

PLoS ONE
Multidisciplinary
2012English

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple Negative Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy